Retevmo (selpercatinib) is a prescription drug used to treat certain types of lung and thyroid cancer. The drug comes as a capsule that you swallow. It’s usually taken twice per day. Retevmo is used ...
If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), ...
Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...
INDIANAPOLIS, Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the ...
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring ...
INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed ...
Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...
Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows its value in an adjuvant lung cancer setting. The LIBRETTO-432 trial showed ...
A preliminary report depicted confusion in the cockpit shortly before an Air India jetliner crashed, killing 260 people last month, after the plane's engine fuel cutoff switches almost simultaneously ...
Retevmo (selpercatinib) is a brand-name drug prescribed for certain types of cancer in adults and some children. Retevmo comes as an oral capsule that’s typically taken twice per day, but the dosage ...
- Approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer - Accelerated approval based on data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results